BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38357982)

  • 21. GATA3 Expression in Common Gynecologic Carcinomas: A Potential Pitfall.
    Terzic T; Mills AM; Zadeh S; Atkins KA; Hanley KZ
    Int J Gynecol Pathol; 2019 Sep; 38(5):485-492. PubMed ID: 30059453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
    Kong CS; Beck AH; Longacre TA
    Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
    Law T; Piotrowski MJ; Ning J; Jiang X; Ding Q; Sahin AA
    Hum Pathol; 2023 Aug; 138():62-67. PubMed ID: 37331526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
    Bartosch C; Manuel Lopes J; Oliva E
    Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group.
    Wentzensen N; du Bois A; Kommoss S; Pfisterer J; von Knebel Doeberitz M; Schmidt D; Kommoss F
    Int J Gynecol Pathol; 2008 Jan; 27(1):18-23. PubMed ID: 18156969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
    Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
    Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
    Huang W; Cheng X; Ji J; Zhang J; Li Q
    Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
    Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection.
    Houghton O; Jamison J; Wilson R; Carson J; McCluggage WG
    Histopathology; 2010 Sep; 57(3):342-50. PubMed ID: 20727021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
    Mondal SK; Basak B; Bhattacharya S; Panda UK
    J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
    Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
    Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas.
    Miller EM; Tymon-Rosario J; Sunkara J; Harmon BE; Karabakhtsian RG; Novetsky AP
    Int J Gynecol Cancer; 2018 Sep; 28(7):1318-1324. PubMed ID: 30036224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas.
    Carleton C; Hoang L; Sah S; Kiyokawa T; Karamurzin YS; Talia KL; Park KJ; McCluggage WG
    Am J Surg Pathol; 2016 May; 40(5):636-44. PubMed ID: 26685087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical carcinomas with serous-like papillary and micropapillary components: illustrating the heterogeneity of primary cervical carcinomas.
    Wong RW; Ng JHY; Han KC; Leung YP; Shek CM; Cheung KN; Choi CKM; Tse KY; Ip PPC
    Mod Pathol; 2021 Jan; 34(1):207-221. PubMed ID: 32699256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
    Rajendran S; McCluggage WG
    Int J Gynecol Pathol; 2022 Mar; 41(2):191-202. PubMed ID: 33782345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms.
    Kubba LA; McCluggage WG; Liu J; Malpica A; Euscher ED; Silva EG; Deavers MT
    Mod Pathol; 2008 Apr; 21(4):485-90. PubMed ID: 18246044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
    McCluggage WG; Sumathi VP; McBride HA; Patterson A
    Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.